PD-L1 Antikörper (AA 39-191)

Produktnummer ABIN6939569

Produktdetails anti-PD-L1 Antikörper

Target: PD-L1 (CD274 (PD-L1))

Bindungsspezifität: AA 39-191

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Coating (Coat)

Aufreinigung: Purified by Protein A/G

Immunogen: Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)

Klon: PDL1-2744

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise:

Positive Control: Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.

Known Application: ELISA (For coating, order antibody without BSA),Western Blot (1-2 μg/mL),Optimal dilution for a specific application should be determined.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 200 μg/mL

Buffer: 10 mM PBS with0.05 % BSA & 0.05 % azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-80 °C

Informationen zur Lagerung: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Haltbarkeit: 24 months

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274 (PD-L1 Produkte)

Synonyme: B7-H antikoerper, B7H1 antikoerper, PD-L1 antikoerper, PDCD1L1 antikoerper, PDCD1LG1 antikoerper, PDL1 antikoerper, A530045L16Rik antikoerper, B7h1 antikoerper, Pdcd1l1 antikoerper, Pdcd1lg1 antikoerper, Pdl1 antikoerper, RGD1566211 antikoerper, CD274 molecule antikoerper, CD274 antigen antikoerper, programmed cell death 1 ligand 2 antikoerper, CD274 antikoerper, Cd274 antikoerper, PDCD1LG2 antikoerper

Hintergrund: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20 % and 15 % identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

Molekulargewicht: 37-50kDa

Gen-ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints